Search results for "FDA update"
Pacemakers, stents recalled; warnings on liver disease drug
This column reviews details on recent recalls, alerts, and approvals.
https://immattersacp.org/archives/2021/07/pacemakers-stents-recalled-warnings-on-liver-disease-drug.htm
1 Jul 2021
Ondansetron 32-mg dose pulled from market
The 32-mg, single intravenous dose of ondansetron hydrochloride (Zofran) has been pulled from the market due to its cardiac risks, the FDA recently announced.
https://immattersacp.org/weekly/archives/2012/12/11/9.htm
11 Dec 2012
Tigecycline gets warning for mortality risk
The next edition is online and coming to your mailbox
https://immattersacp.org/weekly/archives/2010/09/14/7.htm
14 Sep 2010
Liver injuries found in patients on orlistat
Suggest a colleague as a Top Hospitalist
https://immattersacp.org/weekly/archives/2010/06/08/8.htm
8 Jun 2010
Ketorolac, Liposyn recalled for particulate contamination
A summary of approvals, recalls, warnings and alerts digested by ACP Internist from the Food and Drug Administration's alerts.
https://immattersacp.org/archives/2010/01/fda.htm
1 Jan 2010
Bleeding risk of dabigatran under scrutiny
Serious bleeding events have been reported in patients taking dabigatran (Pradaxa), according to a new FDA MedWatch alert.
https://immattersacp.org/weekly/archives/2011/12/13/7.htm
13 Dec 2011
Sibutramine contraindicated in patients with CVD
Propose workshops for future meetings of Internal MedicineNew ACPNet project on low back painPractice improvement Webinars for the Medical Home Builder
https://immattersacp.org/weekly/archives/2010/02/02/9.htm
2 Feb 2010
Risks seen with anemia, asthma drugs; insulin syringes recalled
Warnings, recalls and updates from the Food and Drug Administration.
https://immattersacp.org/archives/2010/04/fda.htm
1 Apr 2010
Details on COVID-19 treatments authorized for outpatients
This column reviews details on recent recalls, alerts, and approvals.
https://immattersacp.org/archives/2022/03/details-on-covid-19-treatments-authorized-for-outpatients.htm
1 Mar 2022
Cardiac risks of testosterone, saxagliptin under investigation
This regulatory update covers an FDA review of the risk of stroke, heart attack and death in men taking testosterone products, as well as a possible increase in heart failure associated with saxagliptin.
https://immattersacp.org/archives/2014/04/fda.htm
1 Apr 2014